

FOI REF: 26/474

4th August 2026**Eastbourne District General Hospital**Kings Drive
Eastbourne
East Sussex
BN21 2UDTel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

I have a Freedom of Information request that I would like to raise.

- 1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?**

7.

- 1a. Of these patients, how many commenced treatment at your trust within the last 6 months?**

6.

- 2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:**

- **R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**

14.

- **R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**

0.

- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine)**

0.

- **Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)**

13.

- **R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)**

0.

- **R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)**

0.

- **R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)**

0.

- **(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)**

0.

- **R-GemOX (rituximab, gemcitabine and oxaliplatin)**

0.

- **Axicabtagene ciloleucel**

0.

- **Tisagenlecleucel**

0.

- **Epcoritamab**

0.

- **Loncastuximab tesirine**

0.

- **Glofitamab**

0.

- **Any other SACT**

5.

- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**

East Sussex Healthcare NHS Trust (ESHT) does not provide a stem cell transplant or bone marrow transplant service.

- **Glofitamab + GemOx (gemcitabine and oxaliplatin)**

0.

3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- **Axicabtagene ciloleucel (Yescarta)**

0.

- **Tisagenlecleucel**

0.

- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine)**

0.

- **R-GemOX (rituximab, gemcitabine and oxaliplatin)**

0.

- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**

ESHT does not provide a stem cell transplant or bone marrow transplant service.

- **Glofitamab + GemOx (gemcitabine and oxaliplatin)**

0.

- **Any other treatments**

1.

4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?

0.

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm